BPI-221351

N/A

Report date: 2025/10/29 15:07:22
NME

Base Information

Drug NameBPI-221351
Drug Alias NameBPI-221351
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIsocitrate dehydrogenase [NADP] cytoplasmic inhibitorsIsocitrate dehydrogenase [NADP], mitochondrial inhibitors
TargetsIsocitrate dehydrogenase [NADP] cytoplasmicIsocitrate dehydrogenase [NADP], mitochondrial
Therapy Area/IndicationsSolid tumoursGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBetta Pharmaceuticals Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBetta Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursGlioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A